LCG
EGRX

Lisanti Capital Growth’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Lisanti Capital Growth’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,995
Closed -$714K – 116
2016
Q4 		$714K Buy
+8,995
New +$653K 0.86% 59

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Lisanti Capital Growth's EGRX Position: Q1 2017 in Review

Lisanti Capital Growth sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 8,995 shares — an estimated $714K sold.

Lisanti Capital Growth first reported a position in EGRX in Q4 2016 and held it in 1 quarter. The position peaked at $714K in Q4 2016. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Lisanti Capital Growth reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Lisanti Capital Growth sold 8,995 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $714K.
  • Lisanti Capital Growth first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Lisanti Capital Growth's Eagle Pharmaceuticals, Inc. position peaked at $714K in Q4 2016.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Lisanti Capital Growth's 13F filing for Q1 2017, filed 12 May 2017.